## Yogesh Punekar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5999359/publications.pdf

Version: 2024-02-01

29	755	15	27
papers	citations	h-index	g-index
30	30	30	1285
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population. Infectious Diseases and Therapy, 2018, 7, 183-195.	4.0	93
2	Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries. PLoS ONE, 2016, 11, e0152618.	2.5	90
3	COPD management costs according to the frequency of COPD exacerbations in UK primary care. International Journal of COPD, 2014, 9, 65.	2.3	89
4	Treatment Evolution after COPD Diagnosis in the UK Primary Care Setting. PLoS ONE, 2014, 9, e105296.	2.5	53
5	Systematic Review of Humanistic and Economic Burden of Symptomatic Chronic Obstructive Pulmonary Disease. Pharmacoeconomics, 2015, 33, 467-488.	3.3	51
6	Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-na $\tilde{A}$ -ve patients infected with HIV-1: a systematic review and network meta-analysis. BMC Infectious Diseases, 2019, 19, 484.	2.9	38
7	Comparison of laboratory- and field-based exercise tests for COPD: a systematic review. International Journal of COPD, 2015, 10, 625.	2.3	34
8	Implications of chronic obstructive pulmonary disease (COPD) on patients' health status: A western view. Respiratory Medicine, 2007, 101, 661-669.	2.9	30
9	Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis. International Journal of COPD, 2015, 10, 2495.	2.3	30
10	Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-na $\tilde{A}$ -ve patients infected with HIV-1: an update on a systematic review and network meta-analysis. BMC Infectious Diseases, 2021, 21, 222.	2.9	26
11	Systematic review of the association between exercise tests and patient-reported outcomes in patients with chronic obstructive pulmonary disease. International Journal of COPD, 2017, Volume 12, 2487-2506.	2.3	24
12	Prevalence and Burden of Dyspnoea Among Patients with Chronic Obstructive Pulmonary Disease in Five European Countries. Pulmonary Therapy, 2016, 2, 59-72.	2.2	23
13	Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis. Respiratory Research, 2017, 18, 86.	3.6	22
14	Effectiveness and safety of dolutegravir twoâ€drug regimens in virologically suppressed people living with HIV: a systematic literature review and metaâ€analysis of realâ€world evidence. HIV Medicine, 2021, 22, 423-433.	2.2	21
15	Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients. Aids, 2019, 33, 1739-1749.	2.2	18
16	Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care. Respiratory Research, 2015, 16, 141.	3.6	15
17	Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis. International Journal of COPD, 2015, 10, 1863.	2.3	14
18	COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners. International Journal of COPD, 2018, Volume 14, 51-63.	2.3	13

#	Article	IF	CITATIONS
19	Resource Use and Costs up to Two Years Post Diagnosis Among Newly Diagnosed COPD Patients in the UK Primary Care Setting: A Retrospective Cohort Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 271-280.	1.6	12
20	Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK. Cost Effectiveness and Resource Allocation, 2015, 13, 22.	1.5	8
21	Comedication prescription patterns and potential for drugâ€drug interactions with antiretroviral therapy in people living with human immunodeficiency virus type 1 infection in Germany. Pharmacoepidemiology and Drug Safety, 2020, 29, 270-278.	1.9	8
22	Prevalence and burden of dyspnoea among COPD patients in Japan. International Journal of Clinical Practice, 2016, 70, 676-681.	1.7	7
23	Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1–Infected Treatment-Naive Patients in Russia. Value in Health Regional Issues, 2018, 16, 74-80.	1.2	7
24	Relationship Between FEV1 and Patient-Reported Outcomes Changes: Results of a Meta-Analysis of Randomized Trials in Stable COPD. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2016, 3, 519-538.	0.7	7
25	Bronchodilator reliever use and its association with the economic and humanistic burden of COPD: a propensity-matched study. Journal of Medical Economics, 2017, 20, 28-36.	2.1	6
26	Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients. Cost Effectiveness and Resource Allocation, 2019, 17, 26.	1.5	5
27	Systematic Review of the Association Between Laboratory- and Field-Based Exercise Tests and Lung Function in Patients with Chronic Obstructive Pulmonary Disease - See more at: http://journal.copdfoundation.org/#sthash.NtJo2ItZ.dpuf. Chronic Obstructive Pulmonary Diseases (Miami. Fla ). 2015. 2. 321-342.	0.7	4
28	Cost Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Combination Therapy Among Symptomatic COPD Patients. Value in Health, 2014, 17, A595.	0.3	3
29	COPD management costs according to the frequency of COPD exacerbations in UK primary care [Corrigendum]. International Journal of COPD, 2014, , 247.	2.3	О